PharmaFocus Today – Page 9 – media

a milestone in the rise of domestic production

In January 2025, the Guizhou Provincial Health Commission launched a centralized procurement project for CT equipment. The total budget of the project is as high as 175.25 million yuan, covering the procurement of 13 sets of CT equipment. Recently, it was announced that the total bid amount for this centralized procurement project was only 78.03 million yuan, which is 44.5% of the budget. Domestic brand CT equipment performed well, and Neusoft Medical became the biggest winner in this bidding, winning 7 sets. 01. Domestic brand wins bid as mainstream The recently announced winning bid for the CT equipment centralized procurement project by the Guizhou Provincial Health Commission shows that the total bid amount for this centralized procurement project is only 78.03 million yuan, which is only 44.5% of the budget and directly saves nearly 100 million yuan in funds. In fierce competition, domestic CT equipment brands have performed well, with ...
- Source: drugdu
- 74
- March 12, 2025
Heavy Ten Year Plan

Recently, Medtronic announced the launch of a “bold” ten-year global plan – Medtronic Spark. 01. Medtronic Spark Program: Lighting the Path to High paying Jobs for Low Income Youth Amidst the global shortage of medical talent, a grand plan aimed at cultivating future leaders in health technology is quietly underway in Galway, Ireland. Global medical technology giant Medtronic has announced the launch of its ten-year “Medtronic Spark” program, aimed at paving a path to high paying health technology careers for one million young people from low-income families. As 2030 approaches, the healthcare and technology industries are facing an unprecedented talent crisis. It is predicted that these two industries will face a total shortage of 15 million professionals, with the health technology sector alone facing a shortage of 4.3 million, and healthcare workers expected to face a huge shortage of 11 million. This severe situation poses a serious challenge to low-income ...
- Source: drugdu
- 69
- March 12, 2025
Sino Biopharmaceuticals and Qingpu Biotechnology Reach Exclusive Cooperation Agreement

Sino Biopharmaceuticals (01177.HK) announced on March 6 that the company recently reached an exclusive cooperation agreement with Nanjing Qingpu Biotechnology Co., Ltd. (hereinafter referred to as “Qingpu Biotechnology”) in mainland China for its developed national Class 2 new drug QP001. According to reports, QP001 is a meloxicam injection registered as a national Class 2 new drug. It is a long-acting, potent new non-steroidal anti-inflammatory drug (NSAIDs) for postoperative pain. Compared with traditional non-selective NSAIDs, QP001 is a selective cyclooxygenase-2 (COX-2) inhibitor that can block the release of COX-2 that causes body pain and inflammation, reduce or block the synthesis of prostaglandins (PGs) in the affected area, thereby playing an anti-inflammatory and analgesic role, while having little effect on cyclooxygenase-1 (COX-1) that maintains normal physiological functions. Therefore, in the future, patients with mild renal impairment, elderly patients and other special groups can also use it normally. China Biopharmaceuticals said that at ...
- Source: drugdu
- 54
- March 12, 2025
Sino Biopharmaceutical’s innovative drug clinical research results are internationally recognized

On March 10, Sino Biopharmaceutical (01177) announced that the Phase Ib/IIa clinical study results of the Group’s independently developed Class 1 innovative drug “Rovadicitinib” for the treatment of chronic graft-versus-host disease (cGVHD) have been published in the top international hematology journal Blood. The drug is the world’s first oral small molecule inhibitor with dual inhibition mechanisms of JAK and ROCK, showing good anti-inflammatory and anti-fibrosis effects. A total of 44 subjects were included in the study, and the results showed that rovadicitinib was well tolerated, with no dose-limiting toxicity. The most common adverse event was anemia, with an incidence of 38.6%. The best overall response rate (BOR) of the study was 86.4%, 72.7% in the glucocorticoid-refractory cohort, and 90.9% in the glucocorticoid-dependent cohort. In addition, 88.6% of the treated subjects reduced their glucocorticoid doses, and 59.1% of the subjects experienced improvement in related symptoms. The Group has submitted a marketing ...
- Source: drugdu
- 60
- March 12, 2025
Yifang Biopharma D-2570 Psoriasis Phase II Clinical Study Results Released

On March 10, Yifang Biopharma (688382) announced that on March 8, 2025, the Phase II clinical study results of the company’s independently developed TYK2 inhibitor D-2570 for the treatment of moderate to severe plaque psoriasis were released in the form of an oral report in the latest breakthrough research abstracts section of the 2025 American Academy of Dermatology Annual Meeting. In terms of safety, D-2570 was generally well tolerated, most adverse events were mild to moderate, and no serious adverse events were reported. Its safety profile is similar to other TYK2 inhibitors, and no new safety signals were found. In addition, data from Phase II clinical studies showed that D-2570 is significantly better than placebo in treating patients with moderate to severe psoriasis, and is also better than similar TYK2 inhibitors currently on the market. It is also comparable in effectiveness to antibody biologics (such as anti-IL-17A and anti-IL-23 antibodies). ...
- Source: drugdu
- 57
- March 12, 2025
When will the HPV vaccine be free? NPC deputies call on the central government to support the vaccination of vulnerable groups

As the most popular self-paid vaccine in the past few years, when the HPV vaccine can become a public product for all has always been the focus of social attention. At the National People’s Congress in recent years, deputies and members have continued to make suggestions on this. Nandu reporters learned that last year, the relevant suggestions were listed as key supervision suggestions by the National Health Commission. This year, deputies and members continued to speak out on this and called for the inclusion of HPV vaccines in the national immunization plan. Because it can prevent cervical cancer, HPV vaccines have been sought after since their birth. The countries that first introduced the vaccination plan have observed a significant decline in HPV infection rates and cervical precancerous lesions. The World Health Organization recommends that 90% of girls should be vaccinated with HPV vaccines before the age of 15 by 2030 ...
- Source: drugdu
- 61
- March 12, 2025
Intelligent regulation of oxygen flow, Weigao takes the lead in launching the first automatic controlled oxygen concentrator

The China Respiratory Science Development Conference pointed out that chronic respiratory problems, represented by chronic obstructive pulmonary disease (COPD), have become the most prominent and severe public health problem in China, with a prevalence rate of 13.7% among people over 40 years old. According to the “Research Report on the Development Trends and Strategies of the Domestic Oxygen Generator Industry from 2023 to 2028” by China Research Institute of Industry, the demand for precision oxygen therapy in the home oxygen therapy market is continuously increasing. Weihai Weigao Health Technology Co., Ltd., a subsidiary of Weigao Group, has taken the lead in launching the first automatic oxygen controlled (AOT) oxygen concentrator to meet the precise oxygen therapy needs of patients, leading the industry development and helping medical progress. 01. Innovative automatic oxygen control technology breaks the limitations of constant oxygen production Traditional oxygen concentrators lack a dynamic adjustment mechanism, making it ...
- Source: drugdu
- 61
- March 11, 2025
Another medical device is scheduled for priority approval

Recently, the Jiangsu Provincial Medical Products Administration released the “Announcement of the Examination Results of Priority Approval Applications for Class II Medical Devices (No. 3 of 2025)”, intending to approve the priority registration process for the ultraviolet phototherapy device of Xuzhou Kono Medical Instrument Equipment Co., Ltd. (hereinafter referred to as “Kono Medical”). Heavy equipment, registration process accelerates Ultraviolet radiation is an invisible light with a wavelength between 100-400nm, which can be divided into UVC radiation (100-280nm), UVB radiation (280-320nm), and UVA radiation (320-400nm). Ultraviolet radiation has sufficient energy to destroy the DNA structure of microorganisms, thus effectively inhibiting the activity of viruses and bacteria. Research has shown that ultraviolet radiation has the effects of accelerating blood circulation, relieving pain, and promoting epithelial regeneration, making it effective in treating diseases such as herpes, psoriasis, and atopic dermatitis. In addition, ultraviolet radiation also promotes the production of vitamin D, which can ...
- Source: drugdu
- 61
- March 11, 2025
Gilead adds new liver disease drug

Seladelar is currently the first and only therapy that has achieved significant improvements in biochemical reactions, normalization of alkaline phosphatase, and relief of itching compared to placebo. This approval means that rare liver disease patients in the European Economic Area (EEA) will have an important new treatment option. From MASH dilemma to PBC breakthrough The development process of Seladelar is full of twists and turns. Originally developed by CymaBay, in 2006, Johnson&Johnson reached a comprehensive development and commercialization agreement with CymaBay Therapeutics for metabolic disease drugs. Johnson&Johnson obtained authorization for three drugs, including Seladelar. In February 2024, Geely Dehao invested $4.3 billion to acquire CymaBay Therapeutics, acquiring the core pipeline drug Seladelar. On August 9, 2024, just one week before the FDA PDUFA date of Seladelar in the United States (August 14), Gilead quickly made a move and purchased Seladelar’s global royalties from Johnson&Johnson for $320 million. Behind this series ...
- Source: drugdu
- 57
- March 11, 2025
Innovative therapy for ALS, updated progress

Source of Medicine Intelligence Network: Medicine Intelligence Network Recently, Shize Biotechnology announced that its self-developed universal iPSC derived subtype neural precursor cell injection product XS-228 injection has been fully approved by the US FDA for registration in clinical trials for the treatment of amyotrophic lateral sclerosis (ALS). This breakthrough not only marks an innovative breakthrough in the field of cell therapy in China, but also brings new hope to patients with ALS. One of the ‘Four Deadly Diseases of the World’ ALS, as one of the “Four Deadly Diseases of the World”, its complexity and harmfulness cannot be ignored. ALS (amyotrophic lateral sclerosis) is a rare and progressive neurodegenerative disease that primarily affects motor neurons in the brain and spinal cord. These neurons are responsible for controlling muscle movement. As they gradually regress and die, patients may experience symptoms such as muscle weakness, atrophy, and stiffness, ultimately leading to the ...
- Source: drugdu
- 54
- March 11, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.